REGN EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
REGN's ev/ebitda is lower than 65% of the last 10 years.
EV/EBITDA History
REGN EV/EBITDA by year
Yearly range of REGN’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 6.5 to 39.0, averaging 17.3.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 11.2 | 13.5 | 15.7 | 14.4 |
| 2025 | 9.6 | 12.5 | 16.0 | 14.2 |
| 2024 | 14.9 | 22.7 | 27.3 | 15.3 |
| 2023 | 14.7 | 17.5 | 20.7 | 20.6 |
| 2022 | 6.5 | 9.7 | 13.4 | 12.6 |
| 2021 | 7.3 | 10.7 | 15.1 | 7.4 |
| 2020 | 13.3 | 19.3 | 26.0 | 13.3 |
| 2019 | 12.4 | 15.2 | 18.2 | 15.7 |
| 2018 | 13.5 | 16.5 | 20.3 | 15.4 |
| 2017 | 20.7 | 29.0 | 38.9 | 21.7 |
| 2016 | 29.4 | 33.6 | 39.0 | 32.1 |
Get notified when REGN EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is REGN EV/EBITDA High or Low Right Now?
Regeneron Pharmaceuticals, Inc.'s EV/EBITDA is currently 14.4, which is below average relative to its 10-year historical range. The 10-year median EV/EBITDA for REGN is approximately 15.9. See all REGN valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.